IMPORTANCE Numerous studies have evaluated the prognostic value of minimal residual disease (MRD) in patients with multiple myeloma (MM). Most studies were small and varied in terms of patient population, treatment, and MRD assessment methods.
gesting that a small but clinically relevant population of myeloma cells not detected by current techniques persists. Assays with greater sensitivity have been developed to detect minimal residual disease (MRD), including multiparameter flow cytometry (MFC), allele-specific oligonucleotide quantitative polymerase chain reaction (ASO-qPCR), and nextgeneration sequencing (NGS) techniques. 3, 4 Potential applications of MRD assessment in MM treatment are numerous. 1, 3, 5, 6 It is already considered an important prognostic factor. 7 Minimal residual disease testing could be used to monitor response to therapy; the presence or absence of MRD may also inform subsequent treatment decisions, including consolidation and maintenance. 7 Historically, owing to the complexity of conventional MRD assays, evaluations were limited to a small number of patients. Recent development of MFC-and NGS-based methods has allowed for MRD assessment in larger studies. To understand the real impact of MRD on outcomes from small-to-mediumsized studies, we performed a meta-analysis of all published data regarding the utility of MRD detection in patients with newly diagnosed MM (NDMM).
Methods

Literature Search and Article Selection
A Medline search was performed for articles published in English between January 1990 and January 2016, using the MeSH terms "multiple myeloma" AND "neoplasm, residual" and the nonMeSH terms "MRD," "myeloma," and "minimal residual disease." Eligible articles included those that reported on controlled trials, randomized controlled trials, or patient cohort studies with MRD status and survival outcomes progression-free survival (PFS) or overall survival (OS) in 20 or more NDMM patients following therapy. Patients could have received any type of treatment except allogeneic stem cell transplantation (alloSCT), and MRD could be assessed by any method (MFC, ASO-qPCR, or NGS), but analysis was restricted to techniques with a limit of detection of 0.01% or lower. Trials were excluded if they: included only patients with relapsed/ refractory MM (RRMM) or smoldering myeloma; assessed MRD in apheresis product; or reported on the same study population used in an already-included trial.
Data Extraction
If primary data were not accessible, survival graphs from relevant trials were carefully measured and a computer program was written to reconstruct the individual survival and censoring times from these measurements. Articles were scrutinized to ensure that all P values, CIs, hazard ratios (HRs), numbers of events/deaths, and median survival times, and durations of patient follow-up matched those reported. There was a PFS curve but not an OS curve for 1 study. 8 However, P values and percentages at particular times were provided for the OS data, which enabled censored values to be used from the PFS curves; it was therefore possible to use the additional information from the article to derive the survival times. For the pooled analysis, data were adjusted to allow for the different proportions of patients with MRD in the different studies. P values are for adjusted log-rank χ 2 tests.
Statistical Analysis
For a pooled analysis of all studies reporting survival data, PFS and OS curves were generated. 9 This method adjusts for the different proportions of MRD positivity and negativity in each study, thereby avoiding inappropriate bias potentially generated by studies with high or low proportions of MRD positivity. The method produces an adjusted log-rank χ 2 statistic to evaluate the significance of any differences between MRD positivity and negativity. It also provides a nonproportional hazards-based equivalent to performing a Cox model analysis stratified by study or group. If the hazards are proportional, the results will be similar to such a Cox model analysis, which was the case in all such analyses in this report. The overview methodology described in detail by Peto 10 was applied. In brief, for PFS and OS, the expected number (E) of events was derived in the MRD-positive and MRDnegative groups for each study, assuming no difference between the MRD groups. This was compared with the observed number (O) of events and the differences (O-Es) were then tested for heterogeneity to see whether the scatter of results was unexpected. 
Results
Literature Search
The initial search yielded 405 articles, and 25 additional articles were identified from the reference sections of recently published articles on the topic. After applying eligibility criteria 21 studies were included in the qualitative assessments ( Figure 1) . 8, [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] Of the 21 articles identified, 13
involved patients with NDMM and in 9 articles it was not reported whether the population was limited to NDMM patients. Sixteen articles involved ASCT-eligible patients and 1 involved ASCT-ineligible patients; the remaining 4 studies included both ASCT-eligible and ASCT-ineligible patients. The primary MRD assays that were evaluated were MFC (n = 9), PCR (n = 11), or NGS (n = 1). Fourteen studies (n = 1273) reported information on the impact of MRD on PFS and 12 (n = 1100) assessed the impact of MRD on OS; these studies were therefore included in the overall quantitative meta-analysis (eTable in the Supplement). Twelve publications reported conventional CR 7 at the time of MRD measurement. 6,8,19,21-27,31 However, further investigation identified potential duplication of data across some studies and led to the exclusion of 5 additional articles from the quantitative analysis in CR patients.
21-24,27
Impact of MRD Status on Survival Outcomes
The overall prognostic value of MRD status in terms of PFS was assessed in 14 studies involving 1273 patients (660 MRD-negative, 613 MRD-positive).
8,12-14,16-18,24,25,28-31
The impact of MRD status on OS was assessed in 12 studies involving 1100 patients (599 MRD-negative, 501 MRD-positive). Figure 2D ). Tests of heterogeneity found no significant differences among the studies for OS (χ 2 = 8.81; df = 11; P = .64) but significant differences among the studies for PFS (χ 2 = 42.1; df = 13; P < .001). This was a result of 2 very small studies, 12,16 which showed unusually large differences;
the Roussel et al 12 study also had no events occurring in MRD negative patients. When these 2 studies were excluded the test for heterogeneity was no longer significant (χ 2 =10.1;df = 11; P = .53).
MRD Superior to Conventional CR for Survival Prediction
To evaluate the impact of MRD status on PFS in patients who had achieved conventional CR, data were pooled from 5 studies involving 574 patients (396 MRD-negative, 178 MRD-positive). Figure 3A) and OS (HR, 0.47; 95% CI, 0.33-0.67; P < .001) ( Figure 3B ). Median PFS was 56 months for MRDnegative patients and 34 months for MRD-positive patients ( Figure 3C ) and median OS was 112 and 82 months, respectively ( Figure 3D) ; PFS rates were 70% and 46% at 3 years, 48% and 27% at 5 years, and 37% and 14% at 7 years, respectively. Similarly, the OS rate was higher for MRD-negative patients compared with MRD-positive patients at 3 years (94% vs 80%), 5 years (80% vs 61%), and 7 years (67% vs 47%). Tests of heterogeneity found no significant differences among the studies for PFS (χ 2 = 2.68; df =4;P = .61) and OS (χ 2 = 4.22; df =5;P = .62). Patients who were MRD-negative but failed to achieve CR had similar PFS and OS as those who were MRD-positive. Further analyses by this group suggested that log reduction in MRD (assessed as a continuous variable, rather than using a threshold for MRD positivity vs negativity), negated the significance of response in multivariate analyses for both PFS and OS.
32
None of the trials directly compared the ability of 2 different treatment approaches to induce MRD-negative status. However, 5 studies evaluated MRD status before and after ASCT.
6,12,17,18,20 All 5 indicated that ASCT increased the proportion of patients with MRD-negative status. 
Discussion
This large-cohort meta-analysis confirms that MRD status has prognostic value and is a valid surrogate marker for both PFS and OS in patients with MM, including those who had achieved a CR. All studies, irrespective of the therapies used, uniformly confirmed the impact of MRD status on outcome, indicating that the predictive value of MRD status was independent of the type of treatment used. This is consistent with the results of a recent study 34 demonstrating that the depth of MRD is the determining factor for subsequent outcome. Findings from this meta-analysis provide quantitative evidence to Overall HR, 0.47 95% CI, 0.33-0.67, P <.001
A and C, Forest plots and survival curves for patients in CR showing the overall effect of MRD status on PFS. B and D, forest plots and survival curves for patients in CR showing the overall effect of MRD status on OS. MRD-negative patients had better outcomes. Tests for heterogeneity indicated no significant differences between the studies for both PFS and OS. Kaplan-Meier curves for PFS (C) and OS (D); data were adjusted to account for the different proportions of patients in each study being MRD-positive and MRD-negative. The sizes of the Forest plot squares are proportional to the amount of information each trial contains (the inverse of the variance); the horizontal lines represent the 95% CIs. CI, confidence interval; MRD, minimal residual disease; OS, overall survival; PFS, progression-free survival.
Research Original Investigation
Association of Minimal Residual Disease With Superior Survival Outcomes in Patients With Multiple Myeloma support the conceptual basis for integrating MRD assessment into the treatment of MM.
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One of the main strengths of this analysis of pooled data from different clinical trials is the method used to generate the PFS and OS curves. These curves were adjusted for each study or group to allow for different proportions of patients with MRD positivity and negativity in the different studies, using methods described in detail elsewhere. 9 This approach avoids the creation of curves that were biased inappropriately by studies with very high or very low proportions of patients with MRD positivity. This analysis did not account for the type of MRD test used in each study. Approaches to testing vary widely 36 ; the sensitivity of different protocols also varies.
4,27,36,37 However, this may represent a strength of the analysis as the results are method-agnostic, ie, it suggests that if MRD is undetectable with a certain level of sensitivity, the results have similar significance irrespective of the method used. The MFC assay is the most widely used method for MRD testing in MM thus far owing to its broad availability, short turnaround time, and relatively low cost. 3 The main limitations of this technique are its lower sensitivity (up to 1 × 10 −4 or1×10 −5 ) and lack of standardization among laboratories.
The ASO-qPCR assay, although sensitive, is cumbersome and is being replaced by NGS-based MRD assessment which is more sensitive than MFC 38,39 or ASO-qPCR, 40 and feasible in up to 90% of MM patients. 41 To assess whether differences in the method of MRD assessment across the studies would impact our findings, we performed additional analyses comparing HRs for OS and PFS according to the 2 major methods of MRD assessment, flow cytometry and PCR. The HR for OS in the MFC studies (n = 923) was 0.60 (95% CI, 0.47-0.76); in the PCR studies (n = 177) it was 0.44 (95% CI, 0.26-0.77). The HR for PFS (n = 1072) in the MFC studies was 0.44 (95% CI, 0.37-0.52); and in the PCR studies (n = 201) it was 0.27 (95% CI, 0.18-0.40). As expected, the HR is slightly greater in the PCR studies as it provides a more sensitive measurement.
The studies in this analysis included primarily NDMM patients, most of whom were undergoing ASCT. The applicability of the results of this analysis in other populations, such as those with transplant-ineligible NDMM, RRMM, or highrisk cytogenetic features, is unclear. In addition, the timing of MRD assessment varied among the studies. For example, among the 14 trials included in the overall PFS metaanalysis, 5 assessed MRD before ASCT and 12 assessed MRD after ASCT. Among the trials assessing MRD after ASCT, most assessed patients after 3 months (or day 100), but some continued to assess patients every 3 to 6 months thereafter. Despite these differences, all studies showed large and consistent effects of MRD, confirmed by the nonsignificant χ 2 statistic for heterogeneity, suggesting that any methodological variations between studies have a relatively minor influence on the overall MRD effect. In addition, there is always a risk in meta-analyses that negative results are less likely to have been reported, eg, lack of effect of MRD status on OS and/or PFS. Lastly, this analysis did not isolate the prognostic effect of MRD from those of post-transplant treatments patients may have received. Future trials will need to focus on some of these questions to determine the clinical utility of MRD assessment as well as its ability to inform treatment decisions.
Assessment of MRD has several important potential applications in treating MM. 1, 42 
